Yaoshibang

What Yaoshibang does

Yaoshibang (药师帮) is a Chinese B2B digital pharmaceutical trading platform founded in 2015 and headquartered in Guangzhou, operating the largest digital pharmaceutical transaction and service network in China's extra-mural (院外) healthcare market per Frost & Sullivan. The company connects pharmaceutical brands, distributors, and wholesalers with pharmacies and grassroots medical institutions, serving 490,000+ pharmacy terminals, 370,000+ grassroots medical institutions, and 11,000+ registered merchants, with coverage spanning 98.9% of Chinese counties and 91.5% of townships. The platform combines a B2B marketplace with a self-operated (自营) resale model, and is publicly listed on the Hong Kong Stock Exchange Main Board (ticker hkg:9885) following its June 2023 IPO, with Hang Seng Stock Connect inclusion in August 2023.

The platform is built on a multi-module SaaS architecture with four purpose-built suites: 药企SaaS (for pharmaceutical brands and manufacturers), 商家SaaS (for distributors, including Galaxy+ procurement management, Xentrum warehouse management, and IntelNex delivery management modules), 药店SaaS (for pharmacies), and 诊所SaaS (for clinics). Underpinning fulfillment is an integrated network of 22 strategic center warehouses supporting data-driven logistics, and the Zhangdianyi (掌店易) field sales app serves pharmaceutical brand representatives with direct-to-terminal marketing. Additional sub-brands including 光谱小屋 and 乐药师 extend into pharmacist services and compliance documentation exchange. The company holds the Class A Internet Drug Third-Party Trading Service Platform License from the NMPA, obtained in November 2016, which is required for internet pharmaceutical trading in China.

Yaoshibang generates revenue through four streams: transaction fees and commissions on its B2B marketplace, margins from self-operated pharmaceutical resales, recurring SaaS subscriptions for the four SaaS suites, and digital marketing services for pharmaceutical brands (live streaming commerce, precision marketing campaigns, data-driven product customization). FY2023 revenue was approximately RMB 17 billion (~USD 2.3 billion) on a GMV of RMB 469 billion, with revenue growing over 17% year-over-year in 2025 and net profit growing more than 4x in the same period. Key brand-side partnerships include Bayer (2019), Harbin Pharmaceutical Group (2021), Yiling Pharmaceutical, and Zhongsheng Pharmaceutical.

Name

Yaoshibang

Legal name

广州速道信息科技有限公司

Website

https://ysbang.cn

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Yaoshibang (药师帮) is China's largest digital B2B pharmaceutical trading platform, connecting 11,000+ merchants with 490,000+ pharmacies and 370,000+ grassroots medical institutions across 98.9% of counties via integrated SaaS suites and 22 strategic warehouses, and is listed on the Hong Kong Stock Exchange (hkg:9885).

Ownership category

akta.pro rank

Product category

Pharmaceutical B2B Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Medical, Dental & Lab Supply Marketplaces (CRAFAHAG)

akta.pro secondary industries

B2B Marketplaces & Wholesale Platforms (BPAMAGAD), Wholesale/B2B Generalist Marketplaces (CRAFAAAF)

Keywords

• Pharmaceutical B2B platform
• Drug distribution marketplace
• Pharmacy procurement
• Pharmaceutical SaaS
• Grassroots healthcare supply

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Digital Commerce or Content

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. B2B Marketplace Transaction Fees: Platform charges transaction fees/commissions from buyers and sellers transacting through the Yaoshibang marketplace. The marketplace connects pharmaceutical brands/distributors with pharmacies and clinics, taking a take-rate on GMV. Yaoshibang operates both a marketplace model and a self-operated (自营) model.
2. Self-Operated (自营) Pharmaceutical Sales: Company directly purchases and resells pharmaceutical products through its own inventory and logistics network, generating revenue from the margin between purchase and sale prices.
3. SaaS Subscription Services: Provides specialized SaaS tools for pharmaceutical companies (药企SaaS), merchants/suppliers (商家SaaS), pharmacies (药店SaaS), and clinics (诊所SaaS). Some tools may carry subscription or licensing fees.
4. Digital Marketing Services for Pharma Brands: Pharmaceutical brands pay for marketing services including live streaming promotions, targeted product promotion directly to retail terminals, and data-driven precision marketing campaigns.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Yaoshibang operates China's largest digital B2B pharmaceutical transaction and service platform, connecting over 11,000 pharmaceutical brand and distributor merchants with approximately 490,000 pharmacy terminals and 370,000 grassroots medical institutions. The platform combines a marketplace model with self-operated (自营) pharmaceutical sales, supported by an integrated network of 22 strategic warehouses and a suite of SaaS tools (药企SaaS, 商家SaaS, 药店SaaS, 诊所SaaS) covering procurement, warehouse, delivery, and financial settlement for the extra-mural pharmaceutical industry.

Product overview

Yaoshibang operates a multi-module SaaS platform serving the external pharmaceutical industry (院外医药产业), providing digital transaction and service infrastructure across four customer segments: pharmaceutical companies (药企SaaS), distributors (商家SaaS), pharmacies (药店SaaS), and clinics (诊所SaaS). The platform combines a B2B marketplace with integrated software tools including Galaxy+ (procurement), Xentrum (warehouse), and IntelNex (delivery) modules, alongside innovative subsidiaries like 掌店易, 光谱小屋, and 乐药师. The ecosystem connects over 11,000 merchants with approximately 490,000 pharmacy terminals and 370,000 primary healthcare institutions, forming China's largest digital pharmaceutical transaction and service network.

Differentiator

Problem solved

Functional benefit

Products and services

• 药企SaaS (Pharma Company SaaS)

Quantifiable outcome

• GMV grew 24% YoY to RMB 469 billion in 2023; Revenue approximately RMB 170 billion in 2023; Revenue grew over 17% in 2025; Net profit grew over 4x in 2025
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Harbin Pharmaceutical Group (哈药集团)coreStrategic or Co-development Partner · 1 March 2021Yaoshibang and Harbin Pharmaceutical Group upgraded their strategic cooperation in March 2021, fully advancing omni-channel digital marketing. Harbin Pharma participated in Yaoshibang's Double-11 (Singles Day) live streaming events in 2020. The partnership covers full-channel digital marketing services using Yaoshibang's platform.
• Yiling Pharmaceutical (以岭药业)minorGTM or Marketing Partner · 1 December 2020Yiling Pharmaceutical conducted its first live streaming debut on Yaoshibang's platform in December 2020, achieving total sales of RMB 5.5 million with over 12,000 purchasing pharmacies participating.
• Zhongsheng Pharmaceutical (众生药业)minorGTM or Marketing Partner · 1 June 2020Zhongsheng Pharmaceutical's Chairman and Group President Chen Yonghong participated in Yaoshibang's 618 live streaming session in June 2020, achieving over RMB 2 million in sales in 60 minutes — described as a landmark event for pharmaceutical live streaming.
• Bayer (拜耳)coreStrategic or Co-development Partner · 1 July 2019Bayer and Yaoshibang reached a strategic cooperation intention in July 2019, focusing on serving the lower-tier market (下沉市场). The partnership aimed to leverage Yaoshibang's digital platform and nationwide geographic coverage to expand Bayer's distribution reach into China's county and township markets.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• 111, Inc. (1药网): 1药网 (111, Inc.) operates a B2B pharmaceutical platform in China connecting pharma manufacturers and distributors with pharmacies and clinics. Direct competitor to Yaoshibang in the digital drug distribution space with similar B2B marketplace and SaaS offerings.

Broad incumbents

• JD Health (京东健康): JD Health is a major Chinese online healthcare platform offering pharmaceutical B2B distribution alongside consumer pharmacy retail and telemedicine services. As a subsidiary of JD.com, it leverages consumer traffic and logistics infrastructure to compete with Yaoshibang in pharma B2B.
• Alibaba Health (阿里健康): Alibaba Health operates a healthcare and pharmaceutical e-commerce ecosystem including B2B drug distribution through its Tmall Medical and legacy platforms. Backed by Alibaba Group, it competes broadly with Yaoshibang in pharma digital commerce.
• Jointown Pharmaceutical (九州通): Jointown is one of China's largest pharmaceutical distributors with extensive nationwide logistics networks covering lower-tier markets. It has invested heavily in digital transformation (Good Doctor Jointown platform) to compete with digital-native platforms like Yaoshibang.
• Sinopharm Group (国药控股): Sinopharm is China's largest state-controlled pharmaceutical distributor and retailer, operating across the entire drug supply chain. While traditionally a wholesaler, its scale and distribution network make it a structural competitor and potential partner for Yaoshibang.
• Shanghai Pharmaceuticals (上海医药): Shanghai Pharmaceuticals is a major Chinese pharmaceutical manufacturer and distributor with significant nationwide distribution reach. Its integrated supply chain and digital initiatives position it as a comparable incumbent competitor in pharma B2B distribution.
• China Resources Pharmaceutical (华润医药): China Resources Pharmaceutical operates one of China's largest pharmaceutical distribution and retail networks. Its extensive lower-tier market coverage and ongoing digitalization make it a relevant incumbent comparable in pharmaceutical distribution.

Emerging players

• Ping An Healthcare and Technology (平安好医生): Ping An Healthcare and Technology is a Chinese online healthcare platform offering telemedicine, drug retail, and healthcare services. While primarily consumer-facing, its drug fulfillment capabilities overlap with Yaoshibang's lower-tier pharmacy services.
• Meituan Medicine (美团买药): Meituan Medicine operates an online pharmacy and drug delivery platform leveraging Meituan's massive delivery network. While primarily consumer-facing, its expansion into B2B fulfillment for pharmacies overlaps with Yaoshibang's grassroots clinic and pharmacy service offerings.
• Yixian Technology (医信科技): Yixian Technology operates a B2B pharmaceutical platform focused on lower-tier pharmacy and clinic supply, similar to Yaoshibang. Its grassroots market focus and digital transaction model make it a relevant niche competitor in pharma distribution digitization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ysb-inc

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yaoshibang